RVL Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.rvlpharma.com
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 442
- Registration Number
- NCT05179577
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT03565887
- Locations
- 🇺🇸
Hernando Eye Institute, Brooksville, Florida, United States
🇺🇸Heart of America Eye, Shawnee Mission, Kansas, United States
🇺🇸Kennar Eye Care, Pittsburg, Kansas, United States
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
- Conditions
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT03536949
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸Danbury Eye Physicians and Surgeons, Danbury, Connecticut, United States
🇺🇸Sarasota Retina Institute, Sarasota, Florida, United States
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT03319732
- Locations
- 🇺🇸
Neuro Pain Medical Center, Fresno, California, United States
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 536
- Registration Number
- NCT03290131
- Locations
- 🇵🇱
Neuro-Medic, Katowice, Poland
🇵🇱"MEDYK" Stanislaw Mazur Sp. z o.o. (LLC) Medical Centre, Rzeszów, Poland
🇵🇱Neurology Center Krzysztof Selmaj, Łódź, Poland
To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS
- Conditions
- Interventions
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Registration Number
- NCT02869425
- Locations
- 🇺🇸
Advance Medical Pain Management & Research Clinic, Miami, Florida, United States
🇺🇸Meridien Research, Tampa, Florida, United States
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT02436759
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT01848041
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01844232
- Locations
- 🇷🇺
Osmotica Study Site-555, Tonnel'nyy, Russian Federation
🇺🇸Osmotica Study Site-161, Plainview, New York, United States
🇺🇸Osmotica Study Site-155, Raleigh, North Carolina, United States
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 353
- Registration Number
- NCT01743651
- Locations
- 🇺🇸
Osmotica Study Site-127, Pittsburgh, Pennsylvania, United States
🇺🇸Osmotica Study Site-129, Seattle, Washington, United States
🇺🇸Osmotica Study Site-131, Cincinnati, Ohio, United States